Related Experiment Video
Updated: Nov 29, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19
Milad Sharifpour1, Srikant Rangaraju2, Michael Liu3
1Department of Anesthesiology and Critical Care, Emory University Hospital, Atlanta, Georgia, United States of America.
Insights
C-reactive protein (CRP) levels are elevated in hospitalized COVID-19 patients and correlate with mortality. Higher CRP levels and later declines indicate increased in-hospital mortality risk.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Biomarkers
Background:
- C-reactive protein (CRP) is an inflammatory marker.
- Elevated CRP levels are observed in COVID-19 patients, potentially indicating disease severity.
Purpose of the Study:
- To investigate the temporal progression of CRP levels in hospitalized COVID-19 patients.
- To determine the association between CRP levels and in-hospital mortality.
Main Methods:
- Retrospective cohort analysis of 268 adult COVID-19 patients admitted to Emory Healthcare ICUs.
- Analysis of at least two CRP values within the first seven days of admission.
- Comparison of CRP levels between patients who died and those who survived.
Main Results:
- Median CRP during hospitalization was 130 mg/L; on ICU admission, it was 169 mg/L.
- Hospitalization-wide median CRP was significantly higher in non-survivors (206 mg/L) vs. survivors (114 mg/L) (p<0.001).
- CRP levels linearly increased, peaking on day 5, with survivors showing lower peak levels and earlier declines.
Conclusions:
- Daily CRP monitoring aids in risk stratification for hospitalized COVID-19 patients.
- Higher CRP levels and delayed decline are associated with increased in-hospital mortality.
- Established CRP thresholds can facilitate prognostication in COVID-19 patients.
Abstract:
Recent studies have reported that CRP levels are elevated in patients with COVID-19 and may correlate with severity of disease and disease progression. We conducted a retrospective cohort analysis of the medical records of 268 adult patients, who were admitted to one of the six cohorted COVID ICUs across Emory Healthcare System and had at least two CRP values within the first seven days of admission to study the temporal progression of CRP and its association with all-cause in-hospital mortality. The median CRP during hospitalization for the entire cohort was 130 mg/L (IQR 82-191 mg/L), and the median CRP on ICU admission was 169 (IQR 111-234). The hospitalization-wide median CRP was significantly higher amongst the patients who died, compared to those who survived [206 mg/L (157-288 mg/L) vs 114 mg/L (72-160 mg/L), p<0.001]. CRP levels increased in a linear fashion during the first week of hospitalization and peaked on day 5. Compared to patients who died, those who survived had lower peak CRP levels and earlier declines. CRP levels were significantly higher in patients who died compared to those who survived (p<0.001). Our findings support the utility of daily CRP values in hospitalized COVID-19 patients and provide early thresholds during hospitalization that may facilitate risk stratification and prognostication.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pneumonia III: Complications and Assessment
Pericarditis II: Clinical Features and Diagnostic Tests
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

